Advertisement

Advertisement

DE:C17 Stock Latest News

Corvus announces initiation of Phase 1b clinical trial of soquelitinib

The FlyCorvus announces initiation of Phase 1b clinical trial of soquelitinib

Corvus Pharmaceuticals’ Earnings Call Signals High-Stakes Expansion

PremiumCompany Announcements

Corvus Pharmaceuticals’ Earnings Call Signals High-Stakes Expansion

2M ago

Analyst Reiterates Buy on Corvus Pharmaceuticals, Maintains $27 Price Target Amid Advancing Clinical Pipeline

PremiumRatings

Analyst Reiterates Buy on Corvus Pharmaceuticals, Maintains $27 Price Target Amid Advancing Clinical Pipeline

2M ago

Corvus Pharmaceuticals reports Q2 EPS (19c), consensus (17c)

PremiumThe Fly

Corvus Pharmaceuticals reports Q2 EPS (19c), consensus (17c)

2M ago

Corvus Pharmaceuticals Announces Board Leadership Transition

PremiumCompany Announcements

Corvus Pharmaceuticals Announces Board Leadership Transition

3M ago

Corvus Stockholders Approve Directors and Governance Proposals

PremiumCompany AnnouncementsCorvus Stockholders Approve Directors and Governance Proposals

4M ago

Buy Rating Reaffirmed on Corvus as Soquelitinib Data Strengthen Thesis; $27 Price Target Maintained

Ratings

Buy Rating Reaffirmed on Corvus as Soquelitinib Data Strengthen Thesis; $27 Price Target Maintained

5M ago

Corvus Pharmaceuticals Unveils Positive Phase 1 Dermatitis Results

Company Announcements

Corvus Pharmaceuticals Unveils Positive Phase 1 Dermatitis Results

5M ago

Corvus Pharmaceuticals reports Q1 EPS (15c), consensus (15c)

PremiumThe Fly

Corvus Pharmaceuticals reports Q1 EPS (15c), consensus (15c)

5M ago

Corvus Pharmaceuticals Announces Board Changes and New Director

PremiumCompany Announcements

Corvus Pharmaceuticals Announces Board Changes and New Director

6M ago

Apple upgraded, Qualcomm downgraded: Wall Street’s top analyst calls

PremiumThe Fly

Apple upgraded, Qualcomm downgraded: Wall Street’s top analyst calls

6M ago

Corvus Pharmaceuticals initiated with a Buy at Goldman Sachs

PremiumThe Fly

Corvus Pharmaceuticals initiated with a Buy at Goldman Sachs

6M ago

Corvus Pharmaceuticals Bets Big on Soquelitinib Pipeline

PremiumCompany AnnouncementsCorvus Pharmaceuticals Bets Big on Soquelitinib Pipeline

7M ago

Corvus Pharmaceuticals Expands Equity Sales Capacity to $200 Million

Company Announcements

Corvus Pharmaceuticals Expands Equity Sales Capacity to $200 Million

7M ago

Corvus Pharmaceuticals price target raised to $33 from $32 at Oppenheimer

The Fly

Corvus Pharmaceuticals price target raised to $33 from $32 at Oppenheimer

7M ago

Corvus Pharmaceuticals files automatic mixed securities shelf

PremiumThe Fly

Corvus Pharmaceuticals files automatic mixed securities shelf

7M ago

PremiumRatings

Corvus Pharmaceuticals: Strengthened Cash Runway and Expanding Soquelitinib Pipeline Underpin Buy Rating and Attractive Risk‑Reward Profile

7M ago

Corvus Pharmaceuticals reports Q4 EPS (15c), consensus (13c)

PremiumThe Fly

Corvus Pharmaceuticals reports Q4 EPS (15c), consensus (13c)

7M ago

Corvus Pharmaceuticals options imply 7.9% move in share price post-earnings

PremiumThe Fly

Corvus Pharmaceuticals options imply 7.9% move in share price post-earnings

7M ago

Corvus Pharmaceuticals options imply 5.5% move in share price post-earnings

PremiumThe FlyCorvus Pharmaceuticals options imply 5.5% move in share price post-earnings

7M ago

CRVS Earnings Report this Week: Is It a Buy, Ahead of Earnings?

Pre-Earnings

CRVS Earnings Report this Week: Is It a Buy, Ahead of Earnings?

7M ago

Corvus Pharmaceuticals price target raised to $30 from $20 at Mizuho

The Fly

Corvus Pharmaceuticals price target raised to $30 from $20 at Mizuho

8M ago

Trending

S&P 500

―

Dow Jones

―

Nasdaq 100

―

More Trending Stocks >